Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1997 1
1998 2
1999 2
2000 2
2001 3
2002 1
2003 2
2004 2
2005 1
2006 2
2007 1
2008 3
2009 3
2010 1
2014 1
2015 2
2019 2
2020 2
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.
Gugliotta G, Castagnetti F, Breccia M, Levato L, Intermesoli T, D'Adda M, Salvucci M, Stagno F, Rege-Cambrin G, Tiribelli M, Martino B, Bocchia M, Cedrone M, Trabacchi E, Cavazzini F, Porretto F, Sorà F, Simula MP, Albano F, Soverini S, Foà R, Pane F, Cavo M, Saglio G, Baccarani M, Rosti G. Gugliotta G, et al. Among authors: porretto f. Haematologica. 2022 Oct 1;107(10):2356-2364. doi: 10.3324/haematol.2021.280175. Haematologica. 2022. PMID: 35385922 Free PMC article. Clinical Trial.
Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib.
Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party. Castagnetti F, et al. Leukemia. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. Epub 2015 Jun 19. Leukemia. 2015. PMID: 26088952 Clinical Trial.
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.
Stella S, Zammit V, Vitale SR, Pennisi MS, Massimino M, Tirrò E, Forte S, Spitaleri A, Antolino A, Siracusa S, Accurso V, Mannina D, Impera S, Musolino C, Russo S, Malato A, Mineo G, Musso M, Porretto F, Martino B, Di Raimondo F, Manzella L, Vigneri P, Stagno F. Stella S, et al. Among authors: porretto f. Int J Mol Sci. 2019 May 6;20(9):2226. doi: 10.3390/ijms20092226. Int J Mol Sci. 2019. PMID: 31064152 Free PMC article.
Differences among young adults, adults and elderly chronic myeloid leukemia patients.
Castagnetti F, Gugliotta G, Baccarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; GIMEMA CML Working Party. Castagnetti F, et al. Ann Oncol. 2015 Jan;26(1):185-192. doi: 10.1093/annonc/mdu490. Epub 2014 Oct 30. Ann Oncol. 2015. PMID: 25361995 Free article. Clinical Trial.
Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study.
Iannitto E, Romano A, Scalzulli PR, Bonanno V, Scalone R, Chiarenza A, Pirosa MC, Caruso AL, Minoia C, Mantuano S, De Santis G, Salerno M, Crescimanno A, Porretto F, Li Gioi F, Ricciuti G, Greco A, Pavone E, Guarini A, Tarantini G, Mannina D, Consoli U, Cascavilla N, Di Raimondo F, Musso M. Iannitto E, et al. Among authors: porretto f. Eur J Haematol. 2020 Jun;104(6):581-587. doi: 10.1111/ejh.13400. Epub 2020 Mar 13. Eur J Haematol. 2020. PMID: 32107795
Bedside anesthesia for painful procedures in onco-hematology.
Mercadante S, Musso M, Villari P, Porretto F, Gioia M. Mercadante S, et al. Among authors: porretto f. J Palliat Med. 2008 Jan-Feb;11(1):8-9. doi: 10.1089/jpm.2007.0188. J Palliat Med. 2008. PMID: 18370884 No abstract available.
Every-other-day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the "Rete Ematologica Pugliese".
Di Renzo N, Melillo L, Porretto F, Dargenio M, Pavone V, Pastore D, Mazza P, Mannina D, Merenda A, Cascavilla N, Greco G, Matera R, Bonizzoni E, Celio L, Musso M. Di Renzo N, et al. Among authors: porretto f. Cancer Med. 2020 Jan;9(1):170-178. doi: 10.1002/cam4.2628. Epub 2019 Nov 14. Cancer Med. 2020. PMID: 31725196 Free PMC article. Clinical Trial.
32 results